Federal court suspends mifepristone mail delivery as restrictions expand
Federal appeals court blocks mifepristone mailing nationwide as Louisiana pursues expanded restrictions.
Event / Politics
Mifepristone Abortion Pill Legal Battle
Ongoing legal disputes over access to mifepristone, including Supreme Court stays and lower court rulings affecting FDA regulations on mail-order distribution and remote prescription of the medication.
3 reported locations
Daily activity
0 articles0 articles
2026-08-17 to 2026-11-14 · UTC publication dates
Coverage begins 2 May, 00:37 UTC
Follow the documented timeline or explore the related reporting.
What happened
5th Circuit Court of Appeals blocks mailing of mifepristone abortion pill
The 5th U.S. Circuit Court of Appeals issued a ruling requiring that mifepristone, an abortion pill, be distributed only in-person at clinics. The decision blocks the FDA allowance that had permitted prescriptions to be mailed to patients. The court ruling stated that every abortion facilitated by the FDA's action cancels Louisiana's ban on medical abortions.
FDA relaxed mifepristone distribution restrictions during COVID-19 pandemic
During the COVID-19 pandemic years, the FDA under President Joe Biden dropped restrictions on mifepristone prescription and distribution. After more than 20 years of monitoring mifepristone use and reviewing dozens of studies involving thousands of women, FDA officials determined that women could safely use the pill without direct medical supervision.
Louisiana attorney general seeks rollback of FDA mifepristone regulations
Louisiana's attorney general and a woman claiming she was coerced into taking abortion pills requested that FDA rules be rolled back to previous restrictions requiring mifepristone to be prescribed and dispensed only in person at clinics.
Supreme Court unanimously preserved access to mifepristone in 2024
The Supreme Court unanimously preserved access to mifepristone in a 2024 decision. However, the ruling sidestepped core issues by determining that anti-abortion doctors who brought the case did not have legal standing to sue.
FDA approved mifepristone in 2000 as safe abortion method
The FDA approved mifepristone in 2000 as a safe and effective way to end early pregnancies. Mifepristone is typically used in combination with a second drug, misoprostol. Initially, the FDA imposed strict limits on prescription and distribution due to rare cases of excessive bleeding.
Supreme Court previously overturned Roe v. Wade in 2022
The Supreme Court issued a 2022 ruling that overturned Roe v. Wade, eliminating abortion as a nationwide constitutional right and allowing states to enforce abortion bans. This decision enabled individual states to restrict or ban abortion access.
FDA under Trump administration conducting new safety review of mifepristone
FDA officials under President Donald Trump stated the agency is conducting a new review of mifepristone's safety at the direction of the president. In court filings, the FDA could not specify when the review might be complete and acknowledged it was still collecting data.
Read the coverage
2 alternative perspectives
Mifepristone access narrows as courts and regulators tighten restrictions
Court blocks mifepristone mailing; federal reviews threaten access to medication used in most U.S. abortions.
Regulatory uncertainty clouds mifepristone's future as review timelines extend
Multiple regulatory reviews and court restrictions create uncertainty over mifepristone's approved status.
Two decades of FDA approval shaped mifepristone's regulatory path
FDA approval in 2000 and pandemic-era relaxed restrictions created mifepristone's modern regulatory framework.
Supreme Court's 2024 Mifepristone Decision Stands as Binding Precedent
Supreme Court's 2024 mifepristone precedent binds lower courts despite post-Roe legal changes.
Court blocks mifepristone mailing as FDA conducts new safety review
Appeals court blocks mifepristone mailing; Trump FDA launches new safety review amid state-level legal challenge.